Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 3.57% on July 28, with a trading volume of 2 billion CNY [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of July 25, 2024, the fund's latest share count was 2.299 billion, with a total size of 4.176 billion CNY, reflecting an increase of 481.58% in shares and 1005.40% in size year-to-date [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 81.63% during the management period [2] - The top holdings of the fund include Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings such as 9.52% for Innovent Biologics and 9.47% for WuXi Biologics [2] - The fund's trading liquidity is notable, with a cumulative trading amount of 42.835 billion CNY over the last 20 trading days, averaging 2.142 billion CNY per day [1][2]
港股创新药ETF（159567）涨3.57%，成交额20.02亿元
Xin Lang Cai Jing·2025-07-28 07:10